DNA Script

France - Le Kremlin-Bicêtre, Île-de-France

• 26/10/2021
• Series C
• $165,000,000

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Related People

Thomas YbertCo Founder

France - Paris, Île-de-France

I founded DNA Script, in 2014, to tackle one of the major challenges in life sciences: being able to write DNA as fast and as simple as reading DNA.

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

LinkedIn https://www.linkedin.com/in/thomasybert/